МАГНИТНО-РЕЗОНАНСНАЯ ТОМОГРАФИЯ В СТАДИРОВАНИИ ЛИМФОМ

Компьютерная томография (КТ), позитронная эмиссионная томография (ПЭТ) с 18F-фтордезоксиглюкозой (ФДГ) и совмещенная одномоментная ПЭТ/КТ наиболее часто используются для первичного стадирования и оценки эффективности терапии при злокачественных лимфомах. Различные технологии магнитно-резонансной томографии, такие как МРТ всего тела и получение диффузионно-взвешенных изображений, могут стать альтернативой ПЭТ/КТ, свободной от ионизирующего излучения. Диффузионно-взвешенные изображения, отличающиеся высокой чувствительностью в отношении обнаружения патологических очагов и возможностью проведения количественной оценки диффузии молекул воды, могут помочь в изучении злокачественной лимфомы. В данной статье рассмотрены преимущества новых методов МРТ для начального стадирования и оценки эффективности терапии при злокачественных лимфомах. 

1. Jaffe E. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. ASH Education Book. 2009; 2009 (1): 523–31.

2. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J. Clin. 2007; 57: 43–66.

3. Zinzani P.L. Lymphoma: diagnosis, staging, natural history, and treatment strategies. Semin. Oncol. 2005; 32 (1 Suppl. 1): S4–S10.

4. Castellino R.A, Podoloff D.A. Diagnostic radiology and nuclear medicine. In: Mauch P.M., Armitage J.O., Diehl V., Hoppe R.T., Weiss L.M. (eds) Hodgkin’s dis￾ease. Philadelphia: Lippincott Williams & Wilkins. 1999: 241–62.

5. Armitage J. Lymphomas. Eds by G. Canellos, T.A. Lister, J.L. Sklar. 1st ed. Philadelphia; London: W.B. Saunders Company; 1998: 439, 449.

6. Mendenhall N.P. Diagnostic procedures and guidelines for the evaluation and follow-up of Hodgkin’s disease. Semin. Radiat. Oncol. 1996; 6: 131–45.

7. Connors J.M. State-of-the-art therapeutics: Hodgkin’s lymphoma. J. Clin. Oncol. 2005; 23: 6400–8.

8. Alberta Provincial Hematology Tumour Team syntesis. Lymphoma. Clinical practice guideline LYHE-002. (2013). Avaiable at: http://www. albertahealthservices.ca/hp/if-hp-cancer-guide-lyne002-lymphoma.pdf

9. Guidelines on Diagnosis and Treatment of Malignant Lymphomas, Lymphoma forum of Ireland. (2010). Avaiable at: http://haematologyireland.org/meetings/documents/Lymphoma-GuidelinesonDiagnosisandTreatmentofMalignantLymphomas.pdf

10. Kwee T.C., Kwee R.M., Nievelstein R.A. Imaging in staging of malignant lymphoma: a systematic review. Blood. 2008; 111: 504–16.

11. Nogami M. et al. Diagnostic performance of CT, PET, side-by-side, and fused image interpretations for restaging of non-Hodgkin lymphoma. Ann. Nucl. Med. 2007; 21: 189–96.

12. Schoder H., Larson S.M., Yeung H.W. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J. Nucl. Med. 2004; 45 (1): 72S–81S.

13. Vermoolen M.A., Kersten M.J., Fijnheer R. Magnetic resonance imaging of malignant lymphoma. Expert Reviews Hematology. 2011; 4 (2): 161–71.

14. Cheson D., Pfistner B., Juweid M.E. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 2007; 25 (5): 579–86.

15. Moskowitz C.H., Schröder H., Teruya-Feldstein J. et al. Risk-adapted dosedense immunochemotherapy determinated by interim FDG￾PET in advanced-stage diffuse large B-cell lymphoma. J. Clin. Oncol. 2010; 28: 1896–903.

16. Vinicombe S., Reznek R.H. Computerized tomography in the staging of Hodgkin’s disease and non￾Hodgkin’s lymphoma. Eur. J. Nucl. Med. 2003; 30 (1): 42–55.

17. La Fougè re C., Hundt W., Bröckel N. et al. Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Eur. J. Nucl. Med. Mol. Imaging. 2006; 33 (12): 1417–25.

18. Kumral A., Olgun N., Uysal K.M., Corapcioglu F., Oren H., Sarialioglu F. Assessment of peripheral lymphadenopathies: experience at a pediatric hematology-oncology department in Turkey. Pediatr. Hematol. Oncol. 2002; 19 (4): 211–8.

19. Adams H.J.A., Kwee T.C., Vermoolen M.A. et al. Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET. Eur. Radiol. 2013; 23: 2271–8.

20. Brepoels L., Stroobants S. PET scanning and prognosis in Hodgkin’s lymphoma. Curr. Opin. Oncol. 2008; 20 (5): 509–16.

21. Delbeke D., Stroobants S., de Kerviler E., Gisselbrecht C., Meignan M., Conti P.S. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Oncologist. 2009; 14 (2): 30–40.

22. Isasi C.R., Lu P., Blaufox M.D. A metaanalysis of 18F-FDG positron emission tomography in the staging and restaging of patients with lymphoma. Cancer. 2005; 104: 1066–74.

23. Kabickova E., Sumerauer D., Cumlivska E. et al. Comparison of 18FFDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin’s disease. Eur. J. Nucl. Med. Mol. Imaging. 2006; 33: 1025–31.

24. Furth C., Denecke T., Steffen I. et al. Correlative imaging strategies implementing CT, MRI, and PET for staging of childhood Hodgkin disease. J. Pediatr. Hematol. Oncol. 2006; 28: 501–12.

25. Hutchings M., Loft A., Hansen M. et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica. 2006; 91; 482–9.

26. Mikhaeel N.G., Hutchings M., Fields P.A. et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade nonHodgkin lymphoma. Ann. Oncol. 2005; 16: 1514–23.

27. Gallamini A., Rigacci L., Merli F. et al. Predictive value of positron emission tomography performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin disease. Haematologica. 2006; 91: 475–81.

28. Elstrom R., Guan L., Baker G. et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003; 101: 3875–6.

29. Itti E., Lin C., Dupuis J. et al. Prognostic value of interim 18FFDG PET in patients with diffuse large B cell lymphoma:SUV-based assessment at four cycles of chemotherapy. J. Nucl. Med. 2009; 50: 527–33.

30. Blodgett T.M., Meltzer C.C., Townsend D.W. PET/CT: form and function. Radiology. 2007; 242: 360–85.

31. Pelosi E., Pregno P., Penna D. et al. Role of whole-body 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. Radiol. Med. 2008; 113: 578–90.

32. Gossmann A., Eich H.T., Engert A. et al. CT and MR imaging in Hodgkin’s disease – present and future. Eur. J. Haematol. 2005; 75 (66): S83–S89.

33. Lister T.A., Crowther D., Sutcliffe S.B. et al. Report of committee converted to discuss the evaluation and staging of patients with Hodgkin’s disease: the Сotswold meeting. J. Clin. Oncol. 1989; 7: 1630–6.

34. Carbone P.P., Kaplan H.S., Musshoff K. et al. Report of the committee on Hodgkin’s disease staging. Cancer. Res. 1971; 26: 1860–1.

35. Kwee T.C., Kwee R.M., Verdonck L.F., Bierings M.B., Nievelstein R.A. Magnetic resonance imaging for the detection of bone marrow involvement in malignant lymphoma. Br. J. Hematol. 2008; 111: 60–8.

36. Basu S., Torigian D., Alavi A. Evolving concept of imaging bone marrow metastasis in the twenty-first century: critical role of FDG-PET. Eur. J. Nucl. Med. Mol. Imaging. 2008; 35 (3): 465–71.

37. Schmidt G.P., Wintersperger B., Graser A., Baur-Melnyk A., Reiser M.F., Schoenberg S.O. High resolution wholebody magnetic resonance imaging applications at 1.5 and 3 Tesla: a comparative study. Invest. Radiol. 2007; 42: 449–59.

38. Schick F. Whole-body MRI at high field: technical limits and clinical potential. Eur. Radiol. 2005; 15: 946–59.

39. Koh D.M., Collins D.J. Diffusion weighted MRI in the body: applications and challenges in oncology. Am. J. Roentgenol. 2007. 188: 1622–35.

40. Kwee T.C., Ludwig I., Uiterwaal C.S. et al. ADC measurements in the evaluation of lymph nodes in patients with non-Hodgkin lymphoma: feasibility study. MAGMA. 2011. 24 (1): 1–8.

41. Kwee T.C., Sandip Basu, Drew A. et al. Evolving importance of diffusion-weighted magnetic resonance imaging in lymphoma. PET Clinics. 2012; 7 (1): 1–138.

42. Kwee T.C., Takahara T., Ochiai R., Nievelstein R.A., Luijten P.R. Diffusion weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur. Radiol. 2008; 18 (9): 1937–52.

43. Kwee T.C., van Ufford H.M., Beek F.J. et al. Whole-body MRI, including diffusion weighted imaging, for the initial staging of malignant lymphoma, comparison to computed tomography. Invest. Radiol. 2009; 44: 683–90.

44. Van Ufford H.M.E., Kwee T.C., Beek F.J. et al. Whole body MRI, including diffusion-weighted imaging, compared to 18F-FDG-PETCT in newly diagnosed lymphoma: initial results. Am. J. Roentgenol. 2011; 196 (3): 662–9.

45. Tilly H., Dreyling M., Group E.G.W. Diffuse large B-cell non-Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010; 21 (5): v172–v174.

46. Inaoka T., Takahashi K., Mineta M., et al. Thymic hyperplasia and thymus gland tumors: differentiation with chemical shift MR imaging. Radiology. 2007; 243: 869–76.

47. Buchbender С., Heusner Т., Lauenstein T.C. et al. Oncologic PET/MRI, Part 1: Tumors of the Brain, Head and Neck, Chest, Abdomen, and Pelvis. J. Nuclear Med. 2012; 53 (6): 928–38.

48. Buchbender С., Heusner Т., Lauenstein T.C. et al. Oncologic PET/MRI, Part 2: Bone Tumors, Soft-Tissue Tumors, Melanoma, and Lymphoma. J. Nuclear Med. 2012; 53 (8): 1244–52.